These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 31243506)

  • 21. The Interaction of Alpha-synuclein with Membranes and its Implication in Parkinson's Disease: A Literature Review.
    Gonzalez-Horta A
    Nat Prod Commun; 2015 Oct; 10(10):1775-8. PubMed ID: 26669123
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Personalized Medicine Approaches in Parkinson's Disease: The Genetic Perspective.
    Gasser T
    J Parkinsons Dis; 2016 Oct; 6(4):699-701. PubMed ID: 27662328
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Brain alpha-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation.
    Tong J; Wong H; Guttman M; Ang LC; Forno LS; Shimadzu M; Rajput AH; Muenter MD; Kish SJ; Hornykiewicz O; Furukawa Y
    Brain; 2010 Jan; 133(Pt 1):172-88. PubMed ID: 19903734
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunotherapy targeting α-synuclein, with relevance for future treatment of Parkinson's disease and other Lewy body disorders.
    Lindström V; Ihse E; Fagerqvist T; Bergström J; Nordström E; Möller C; Lannfelt L; Ingelsson M
    Immunotherapy; 2014; 6(2):141-53. PubMed ID: 24491088
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Contribution of cholesterol and oxysterols to the pathophysiology of Parkinson's disease.
    Doria M; Maugest L; Moreau T; Lizard G; Vejux A
    Free Radic Biol Med; 2016 Dec; 101():393-400. PubMed ID: 27836779
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Can the disease course in Parkinson's disease be slowed?
    Korczyn AD; Hassin-Baer S
    BMC Med; 2015 Dec; 13():295. PubMed ID: 26653056
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeted Therapies for Parkinson's Disease: From Genetics to the Clinic.
    Sardi SP; Cedarbaum JM; Brundin P
    Mov Disord; 2018 May; 33(5):684-696. PubMed ID: 29704272
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alpha-synuclein: Pathology, mitochondrial dysfunction and neuroinflammation in Parkinson's disease.
    Rocha EM; De Miranda B; Sanders LH
    Neurobiol Dis; 2018 Jan; 109(Pt B):249-257. PubMed ID: 28400134
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impairment of mitochondria dynamics by human A53T α-synuclein and rescue by NAP (davunetide) in a cell model for Parkinson's disease.
    Melo TQ; van Zomeren KC; Ferrari MF; Boddeke HW; Copray JC
    Exp Brain Res; 2017 Mar; 235(3):731-742. PubMed ID: 27866262
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chronic intranasal deferoxamine ameliorates motor defects and pathology in the α-synuclein rAAV Parkinson's model.
    Febbraro F; Andersen KJ; Sanchez-Guajardo V; Tentillier N; Romero-Ramos M
    Exp Neurol; 2013 Sep; 247():45-58. PubMed ID: 23531432
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of rodent models in advancing precision medicine for Parkinson's disease.
    Simons E; Fleming SM
    Handb Clin Neurol; 2023; 193():3-16. PubMed ID: 36803818
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neuropathology of α-synuclein propagation and braak hypothesis.
    McCann H; Cartwright H; Halliday GM
    Mov Disord; 2016 Feb; 31(2):152-60. PubMed ID: 26340605
    [TBL] [Abstract][Full Text] [Related]  

  • 33. α-Synuclein and Lewy pathology in Parkinson's disease.
    Kalia LV; Kalia SK
    Curr Opin Neurol; 2015 Aug; 28(4):375-81. PubMed ID: 26110807
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of a highly neurotoxic α-synuclein species inducing mitochondrial damage and mitophagy in Parkinson's disease.
    Grassi D; Howard S; Zhou M; Diaz-Perez N; Urban NT; Guerrero-Given D; Kamasawa N; Volpicelli-Daley LA; LoGrasso P; Lasmézas CI
    Proc Natl Acad Sci U S A; 2018 Mar; 115(11):E2634-E2643. PubMed ID: 29487216
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Investigational α-synuclein aggregation inhibitors: hope for Parkinson's disease.
    Török N; Majláth Z; Szalárdy L; Vécsei L
    Expert Opin Investig Drugs; 2016 Nov; 25(11):1281-1294. PubMed ID: 27677932
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Small molecule-mediated stabilization of vesicle-associated helical α-synuclein inhibits pathogenic misfolding and aggregation.
    Fonseca-Ornelas L; Eisbach SE; Paulat M; Giller K; Fernández CO; Outeiro TF; Becker S; Zweckstetter M
    Nat Commun; 2014 Dec; 5():5857. PubMed ID: 25524885
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Applying chaperones to protein-misfolding disorders: molecular chaperones against α-synuclein in Parkinson's disease.
    Chaari A; Hoarau-Véchot J; Ladjimi M
    Int J Biol Macromol; 2013 Sep; 60():196-205. PubMed ID: 23748003
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Progress towards therapies for disease modification in Parkinson's disease.
    Vijiaratnam N; Simuni T; Bandmann O; Morris HR; Foltynie T
    Lancet Neurol; 2021 Jul; 20(7):559-572. PubMed ID: 34146514
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunotherapy in Parkinson's disease: Current status and future directions.
    Chatterjee D; Kordower JH
    Neurobiol Dis; 2019 Dec; 132():104587. PubMed ID: 31454546
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting α-Synuclein in Parkinson's Disease: Progress Towards the Development of Disease-Modifying Therapeutics.
    Savitt D; Jankovic J
    Drugs; 2019 Jun; 79(8):797-810. PubMed ID: 30982161
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.